Gerd Auffarth
Director · Outlook Therapeutics, Inc.
Individual
- 2024
- Oct 1, 2025
- 2
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Gerd Auffarth files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Ghiath M. Sukhtian - $7.50M in OTLK purchases and sales in the last 12 months
- Kurt J. Hilzinger - $177K in OTLK purchases and sales in the last 12 months
- Faisal Ghiath Sukhtian - $150K in OTLK purchases and sales in the last 12 months
- Yezan Munther Haddadin - $39K in OTLK purchases and sales in the last 12 months
- Randy H. Thurman - $2K in OTLK purchases and sales in the last 12 months
- Robert Charles Jahr - OTLK
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Gerd Auffarth?
Gerd Auffarth is a corporate insider, tracked as Director of Outlook Therapeutics, Inc. (OTLK). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Gerd Auffarth last file a Form 4?
The most recent primary Form 4 on record is dated 1 October 2025, one of 2 filings going back to 2024.